Background: Prostate cancer is a prevalent and serious health concern among men, with various treatment options available, including androgen deprivation therapy (ADT), radiotherapy, and surgery, each having distinct outcomes.
Objective: This study evaluates the treatment outcomes of prostate cancer patients at Sohag University Hospital from 2017 to 2021.
Patients and Methods: A retrospective cohort study was conducted on 49 prostate cancer patients. Data on demographics, cancer staging, Gleason scores, treatment modalities, and outcomes were analyzed.
Results: The mean age of patients was 70.51 years. A significant proportion (53.1%) were diagnosed with high-risk locally advanced prostate cancer, and 42.9% had metastatic cancer. ADT was administered to 95.9% of patients, and 38.8% received radiotherapy. Overall survival (OS) rates were 100% at 1 year, 88.9% at 3 years, and 66.7% at 5 years. The duration of hormonal treatment significantly impacted OS, while no significant differences were noted across age, T stage, and Gleason score subgroups.
Conclusions: The study highlights the severity of treated prostate cancer cases and the high overall survival rates. The duration of hormonal treatment was a significant factor in overall survival, emphasizing the importance of treatment duration management.